Overview Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) Status: Completed Trial end date: 2009-06-01 Target enrollment: Participant gender: Summary The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D. Phase: Phase 3 Details Lead Sponsor: AGI Therapeutics, Inc.